Australian biopharmaceutical company CSL Ltd surged 24.15% in a single week to A$169.41 after reporting FY2026 results that included impairments but exceeded profit guidance. The stock’s weekly gain followed a statutory loss of A$2.6 billion, driven primarily by A$7.1 billion in impairments related to the Vifor acquisition. Underlying net profit after tax attributable to shareholders fell 2% to US$3.1 billion, yet remained above consensus expectations.
Analysts at UBS, CLSA and Citi raised their price targets, citing a "reset year" that cleared impairments and demonstrated resilient demand for immunoglobulin in CSL’s core Behring division. UBS lifted its target to A$181 from A$158, CLSA to A$180 from A$130, and Citi to A$160 from A$110. InvestingPro’s fair value estimate sits at A$192.99, implying 13.9% upside from current levels. The average target among brokers now ranges between A$180 and A$193.
CSL also announced a A$1.1 billion share buyback program for FY27 and reaffirmed guidance for ~5% profit growth, exceeding the ~2% consensus. The company reported cost savings of A$176 million in FY26 and targets A$550 million by FY28. However, revenue from the Vifor unit is expected to decline approximately 25% in FY27 due to ongoing headwinds.
Despite the strong rally, technical indicators suggest the stock is deeply overbought. The daily Relative Strength Index (RSI) stands at 82.3, while the Average Directional Index (ADX) at 53.8 signals a strong trend. Weekly metrics remain bullish with an RSI of 67.0, but monthly readings show a sell signal with an RSI of 43.9 and ADX of 54.0. The stock faces resistance at A$174.91 and A$178.63, with support at A$168.50.
CSL’s market capitalization now stands at A$82 billion, with a forward price-to-earnings ratio of 19.0x and a dividend yield of 2.4%. The company’s beta is 0.09, indicating low volatility relative to the broader market.
